antiviral news

Press Releases in the global landscape
May 12, 2025

Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M

BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the successful completion of the dose optimization of its antiviral drug ProLectin-M in a randomized double-blind placebo-controlled trial. Preliminary results are expected, with full data submission to the FDA under Bioxytran’s active Investigational New Drug (IND) clinical trials for ProLectin-M.
Read More »
May 12, 2025

Real-world evidence shows remdesivir tied to less death in hospitalized COVID patients

Overall, the hazard ratio for in-hospital mortality at 28 days was 0.73.
Read More »
May 11, 2025

New COVID-19 Drug Shows Greater Promise Against Resistant Viral Strains.

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment. 
Read More »
May 5, 2025

Trump chooses chloroquina defender to take up US management against pandemics

Steven Hatfill promoveu uso do medicamento contra malária para tratar Covid-19 mesmo sem evidências de eficácia
Read More »
Apr 30, 2025

Paxlovid Filed for Pediatric Label Expansion in Japan: Pfizer

Pfizer Japan said on April 28 that it has filed its oral COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) for a wider label to include its use in children six years of age and older who weigh at least 20 kg.
Read More »
Apr 30, 2025

New antiviral compounds show broad protection against COVID-19 variants

Novel Mpro inhibitors exhibit broad activity against SARS-CoV-2 and other coronaviruses.
Read More »